Porous Fe/Cu Nanoreactor with Dual Insurance Design for Precision Chemotherapy and Chemodynamic Therapy DOI
Xianyu Zhu,

Lingli Gao,

Yanbo Zheng

et al.

Advanced Healthcare Materials, Journal Year: 2025, Volume and Issue: unknown

Published: March 24, 2025

Abstract Poor prognosis and chemotherapy response stem from difficulties in precise targeting the lack of effective synergistic treatments. Nanozymes show promising potential tumor chemodynamic therapy (CDT) by catalyzing hydrogen peroxide (H₂O₂) decomposition glutathione depletion microenvironment (TME). However, integrating with CDT remains challenging. In this study, a porous Fe/Cu bimetallic nanozyme carrier (FeCuNPs) is developed for co‐loading humanized 3F8 anti‐GD2 disialoganglioside antibody (3F8) novel pyridazinone‐based chemotherapeutic agent (IMB), forming nanoreactor (3F8@FeCuNPs@IMB) targeted CDT. The responds specifically to acidic TME as primary insurance, allowing controlled release IMB at site. coating on surface acts secondary minimizing drug leakage during delivery process ensuring chemotherapy. Furthermore, FeCuNPs act peroxidase‐like (POD) oxidase‐like (GSHOX) enzymes, hydroxyl radical (•OH) generation depleting excess GSH, enhancing results vitro vivo indicate that dual insurance designed 3F8@FeCuNPs@IMB offers prospect targeted, precise, combination against melanoma.

Language: Английский

Nanozyme-Based Strategies in Cancer Immunotherapy: Overcoming Resistance to Enhance Therapeutic Efficacy DOI Creative Commons
Guangjian Hou, Yukun Xu, Chunhua Wang

et al.

Aging and Disease, Journal Year: 2025, Volume and Issue: unknown, P. 0 - 0

Published: Jan. 1, 2025

Nanozymes, which are nanomaterials that replicate the catalytic activities of natural enzymes in biological systems, have recently demonstrated considerable potential improving cancer immunotherapy by altering tumor microenvironment. Nanozyme-driven immune responses represent an innovative therapeutic modality with high effectiveness and minimal side effects. These nanozymes activate system to specifically recognize destroy cells. Combined immunotherapeutic agents, can amplify anti-cancer integrating remodeling immunogenic cell death (ICD). This review offers a thorough discussion about various involved immunity, including those mimicking catalase (CAT), superoxide dismutase (SOD), peroxidase (POD), oxidase (OXD). It also discusses challenges future directions for translating nanozyme platforms into clinical applications, enhancing susceptibility cells immunotherapy. Nanozyme-based strategies substantial oncology, offering new effective options management.

Language: Английский

Citations

0
Porous Fe/Cu Nanoreactor with Dual Insurance Design for Precision Chemotherapy and Chemodynamic Therapy DOI
Xianyu Zhu,

Lingli Gao,

Yanbo Zheng

et al.

Advanced Healthcare Materials, Journal Year: 2025, Volume and Issue: unknown

Published: March 24, 2025

Abstract Poor prognosis and chemotherapy response stem from difficulties in precise targeting the lack of effective synergistic treatments. Nanozymes show promising potential tumor chemodynamic therapy (CDT) by catalyzing hydrogen peroxide (H₂O₂) decomposition glutathione depletion microenvironment (TME). However, integrating with CDT remains challenging. In this study, a porous Fe/Cu bimetallic nanozyme carrier (FeCuNPs) is developed for co‐loading humanized 3F8 anti‐GD2 disialoganglioside antibody (3F8) novel pyridazinone‐based chemotherapeutic agent (IMB), forming nanoreactor (3F8@FeCuNPs@IMB) targeted CDT. The responds specifically to acidic TME as primary insurance, allowing controlled release IMB at site. coating on surface acts secondary minimizing drug leakage during delivery process ensuring chemotherapy. Furthermore, FeCuNPs act peroxidase‐like (POD) oxidase‐like (GSHOX) enzymes, hydroxyl radical (•OH) generation depleting excess GSH, enhancing results vitro vivo indicate that dual insurance designed 3F8@FeCuNPs@IMB offers prospect targeted, precise, combination against melanoma.

Language: Английский

Citations

0